Table 3 Results of cost and effectiveness outcomes and cost-effectiveness analyses
| Â | FDG-PET/CT group | Standard CT group | Difference / ICER / NMB | ||||||
|---|---|---|---|---|---|---|---|---|---|
Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | ||||
Total cost | 49,563 | 36,867 | 65,133 | 57,574 | 44,837 | 73,347 | -8,011 | -27,998 | 13,986 |
QALY | 0.285 | 0.283 | 0.287 | 0.284 | 0.282 | 0.286 | 0.001 | -0.001 | 0.004 |
ICER: Cost per QALY gained | FDG-PET/CT dominates a | -23,165,055 | 30,415,796 | ||||||
NMB at WTP = $50,000 | 8,082 | -13,459 | 29,624 | ||||||
NMB at WTP = $100,000 | 8,154 | -13,516 | 29,823 | ||||||
Antimicrobial rationalisation | 81.8% | 71.9% | 91.2% | 65.1% | 51.7% | 76.2% | 16.7% | -0.3% | 33.0% |
ICER: Cost per patient change in antimicrobial therapy | FDG-PET/CT dominates a | -446,892 | 161,378 | ||||||
Mortality at 6 months | 16.3% | 6.3% | 31.0% | 18.6% | 7.9% | 34.5% | -2.3% | -17.9% | 13.1% |
ICER: Cost per death averted | FDG-PET/CT dominates a | -1,976,110 | 2,207,504 | ||||||